Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas.N Engl J Med. 1984;311:1471–1475. ArticlePubMedCAS Google Scholar
Biologic response modifiers: a report.Natl Cancer Inst Monogr. 1983;63:57–59.
Fefer A. Interleukin-2: clinical applications—hematologic malignancies. In: Rosenberg SA, ed.Principles and Practice of the Biologic Therapy of Cancer. 3rd ed. Philadelphia: Lippincott Williams &Wilkins; 2000:83–92. Google Scholar
Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Anti-idiotype antibodies can induce long term complete remissions in non-Hodgkin’s lymphoma patients without eradicating the malignant clone.Blood. 1998;92:1184–1190. ArticlePubMedCAS Google Scholar
McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998;16:2825–2833. ArticlePubMedCAS Google Scholar
Timmerman JM, Levy R. The history of the development of vaccines for lymphoma.Clin Lymphoma. 2000;1:129–139. ArticlePubMedCAS Google Scholar
Talpaz M, Ravandi F, Kurzock R, Estrov Z, Kantarjian HM. Inter-feron-alpha and beta: clinical applications—leukemias, lymphomas, and multiple myeloma. In: Rosenberg SA, ed:Principles and Practice of the Biologic Therapy of Cancer. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2000:209–224. Google Scholar
Allen IE, Ross SD, Borden SP, et al. Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin’s lymphoma.J Immunother. 2001;24:58–65. ArticlePubMedCAS Google Scholar
Rohatiner A, Radford J, Deakin D, et al. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma.Br J Cancer. 2001;85: 29–35. ArticlePubMedPubMed CentralCAS Google Scholar
Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients.Ann Oncol. 2000;11:1427–1436. ArticlePubMedCAS Google Scholar
Gisselbrecht C, Maraninchi D, Pico JL, et al. Interleukin-2 treatment in lymphoma: a phase II multicenter study.Blood. 1994;83: 2081–2085. ArticlePubMedCAS Google Scholar
Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.Nat Med. 1998;4: 321–327. ArticlePubMedPubMed CentralCAS Google Scholar
Shimizu K, Fields RC, Giedlin M, Mule JJ. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.Proc Natl Acad Sci USA. 1999;96:2268–2273. ArticlePubMedCAS Google Scholar
Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy.Cytokine Growth Factor Rev. 2002;13:155–168. ArticlePubMedCAS Google Scholar
Younes A, Robertson MJ, Flinn I, et al. A phase II study of interleukin-12 in patients with relapsed non-Hodgkin lymphoma and Hodgkin’s disease [abstract].Blood. 2002;100:364a. Abstract 1408. Article Google Scholar
Ansell SM, Witzig TE, Kurtin PJ, et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.Blood. 2002;99:67–74. ArticlePubMedCAS Google Scholar
Gajewski TF, Fallarino F, Ashikari A, Sherman M. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.Clin Cancer Res. 2001;7:895s-901s. PubMedCAS Google Scholar
Gong J, Koido S, Chen D, et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.Blood. 2002;99:2512–2517. ArticlePubMedCAS Google Scholar
Curti A, Parenza M, Colombo MP. Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma.Blood. 2003;101:568–575. ArticlePubMedCAS Google Scholar
Rosen ST, ed. Current and ongoing clinical development of immunotherapy in B cell malignancies.Semin Oncol. 2002; 29(suppl 2):1–124. ArticlePubMed Google Scholar
Linenberger ML, Maloney DG, Bernstein ID. Antibody-directed therapies for hematological malignancies.Trends Mol Med. 2002; 8:69–76. ArticlePubMedCAS Google Scholar
Stevenson GT, Elliott EV, Stevenson FK. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target.Fed Proc. 1977;36:2268–2271. PubMedCAS Google Scholar
Hall SS. “Dr.Levy’s Favorite Guinea Pig”: A Commotion in the Blood. New York: Henry Holt; 1997:391–408. Google Scholar
Levy R, Dilley J. Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization.Proc Natl Acad Sci USA. 1978;75:2411–2415. ArticlePubMedCAS Google Scholar
Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.N Engl J Med. 1982;306:517–522. ArticlePubMedCAS Google Scholar
Maloney DG. Monoclonal antibodies. In: Mendelsohn J, Howley P, Israel M, Liotta L, eds.The Molecular Basis of Cancer. 2nd ed. Philadelphia: WB Saunders; 2001:467–501. Google Scholar
Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.Blood. 1994;83:435–445. ArticlePubMedCAS Google Scholar
Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance.Semin Oncol. 2002;29(suppl 2):2–9. ArticlePubMedCAS Google Scholar
Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.Nat Med. 2000;6:443–446. ArticlePubMedCAS Google Scholar
Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.Blood. 2001;98:1352–1357. ArticlePubMedCAS Google Scholar
Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.Blood. 2002;99:754–758. ArticlePubMedCAS Google Scholar
Davis TA, Maloney DG, Grillo-Lopez AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma with rituximab and interferon-alpha-2a.Clin Cancer Res. 2000;6:2644–2652. PubMedCAS Google Scholar
Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin’s lymphoma.Br J Haematol. 2002;117:828–834. ArticlePubMedCAS Google Scholar
Warren TL, Weiner GJ. Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma.Semin Oncol. 2002;29(suppl 2):93–97. ArticlePubMedCAS Google Scholar
Leonard JP, Link BK. Immunotherapy of non-Hodgkin’s lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).Semin Oncol. 2002;29(suppl 2):81–86. ArticlePubMedCAS Google Scholar
Leonard JP, Coleman M, Matthews JC, et al. Phase I/II trial of Epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin’s lymphoma (NHL) [abstract].Blood. 2002;100:358a. Abstract 1388. Google Scholar
Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.Blood. 2002;99:3554–3561. ArticlePubMedCAS Google Scholar
Hopkins M, Pathan N, Chu P, Grint P, Saven A. IDEC-152 (Anti- CD23) triggers apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro [abstract].Blood. 2002;100:597a. Abstract 2346. Google Scholar
Czuczman M, Witzig TE, Younes A, et al. IDEC-114, an anti-CD80 monoclonal antibody for relapsed of refractory, follicular NHL: phase I/II study of safety, efficacy, and pharmacokinetics [abstract].Blood. 2002;100:163a. Abstract 610. Google Scholar
Nagy ZA, Hubner B, Lohning C, et al. Fully human, HLA-DR- specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells.Nat Med. 2002;8:801–807. ArticlePubMedCAS Google Scholar
French RR, Chan HT,Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.Nat Med. 1999;5:548–553. ArticlePubMedCAS Google Scholar
Tutt AL, O’Brien L, Hussain A, Crowther GR, French RR, Glennie MJ. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.J Immunol. 2002;168:2720–2728. ArticlePubMedCAS Google Scholar
van Mierlo GJ, den Boer AT, Medema JP, et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.Proc Natl Acad Sci USA. 2002;99:5561–5566. ArticlePubMedCAS Google Scholar
Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.Nat Med. 1999;5:780–787. ArticlePubMedCAS Google Scholar
Vonderheide RH, Dutcher JP, Anderson JE, et al. Phase I study of recombinant human CD40 ligand in cancer patients.J Clin Oncol. 2001;19:3280–3287. ArticlePubMedCAS Google Scholar
Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.N Engl J Med. 1992;327:1209–1215. ArticlePubMedCAS Google Scholar
Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: long-term results of a clinical trial.Blood. 1997;89:3129–3135. ArticlePubMedCAS Google Scholar
Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells.Annu Rev Immunol. 2000;18:767–811. ArticlePubMedCAS Google Scholar
Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy.Annu Rev Med. 1999;50:507–529. ArticlePubMedCAS Google Scholar
Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.Nat Med. 1996;2:52–58. ArticlePubMedCAS Google Scholar
Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.Blood. 2002;99:1517–1526. ArticlePubMedCAS Google Scholar
Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.Proc Natl Acad Sci USA. 1996;93:10972–10977. ArticlePubMedCAS Google Scholar
Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulo- cyte-monocyte colony-stimulating factor against lymphoma.Nat Med. 1999;5:1171–1177. ArticlePubMedCAS Google Scholar
Wilson WH, Neelapu S, White T, et al. Idiotype vaccine following EPOCH-Rituximab treatment in untreated mantle cell lymphoma [abstract].Blood. 2002;100:162a. Abstract 608. Google Scholar
Timmerman JM, Czerwinski D, Taid B, et al. A phase I/II trial to evaluate the immunogenicity of recombinant idiotype protein vaccines for the treatment of non-Hodgkin’s lymphoma (NHL).Blood. 2000;96:578a. Google Scholar
Timmerman J, Vose J, Kunkel L, et al. A phase 2 study demonstrating recombinant idiotype vaccine elicits specific anti-idiotype immune responses in aggressive non-Hodgkin’s lymphoma [abstract].Blood. 2001;98:341a. Abstract 1440. Google Scholar
Redfern C, Guthrie TH, Smith MR, et al. A phase I trial of FavId (Id-KLH) for relapsed indolent non-Hodgkin’s lymphoma [abstract].Blood. 2002;100:357a. Abstract 1383. Google Scholar
McCormick AA, Kumagai MH, Hanley K, et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants.Proc Natl Acad Sci USA. 1999;96:703–708. ArticlePubMedCAS Google Scholar
Reddy SA, Czerwinski DK, Rajapaksa R, et al. Plant derived single chain Fv idiotype vaccines are safe and immunogenic in patients with follicular lymphoma: results of a phase I study [abstract].Blood. 2002;100:163a. Abstract 609. Google Scholar
Osterroth F, Garbe A, Fisch P, Veelken H. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells.Blood. 2000;95:1342–1349. ArticlePubMedCAS Google Scholar
Veelken H, Mauerer K, Waller CF, Eckerman E, Simon F, Osterroth F. A phase I trial of a recombinant idiotype vaccine for active immunization against refractory NHL [abstract].Ann Oncol. 2002; 13:40.Abstract 120. Google Scholar
Krieg AM, Yi AK, Hartmann G. Mechanisms and therapeutic applications of immune stimulatory CpG DNA.Pharmacol Ther. 1999;84:113–120. ArticlePubMedCAS Google Scholar
Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma.Nat Med. 1996;2: 1038–1041. ArticlePubMedCAS Google Scholar
King CA, Spellerberg MB, Zhu D, et al. DNA vaccines with single- chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma.Nat Med. 1998;4: 1281–1286. ArticlePubMedCAS Google Scholar
Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity.Nat Biotechnol. 1999;17:253–258. ArticlePubMedCAS Google Scholar
Timmerman JM, Singh G, Hermanson G, et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.Cancer Res. 2002;62:5845–5852. PubMedCAS Google Scholar
Zhu D, Rice J, Savelyeva N, Stevenson FK. DNA fusion vaccines against B-cell tumors.Trends Mol Med. 2001;7:566–572. ArticlePubMedCAS Google Scholar
Biragyn A, Surenhu M, Yang D, et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens.J Immunol. 2001;167:6644–6653. ArticlePubMedCAS Google Scholar
Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long- lasting anti-tumor immunity.Proc Natl Acad Sci USA. 1993;90:3539–3543. ArticlePubMedCAS Google Scholar
Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.Proc Natl Acad Sci USA. 1998;95:13141–13146. ArticlePubMedCAS Google Scholar
Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.Cancer Res. 1997;57:1537–1546. PubMedPubMed CentralCAS Google Scholar
Nemunaitis J, Sterman D, Jablons D, et al. A phase I/II study of autologous GM-CSF gene-modified cancer vaccines in subjects with non-small cell lung cancer [abstract].Proc Am Soc Clin Oncol. 2001;20:254a. Abstract 1019. Google Scholar
Levitsky HI, Montgomery J, Ahmadzadeh M, et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.J Immunol. 1996;156:3858–3865. PubMedCAS Google Scholar
Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI. Sustaining the graft-versus-tumor effect through post-transplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines.Blood. 2000;95:3011–3019. ArticlePubMedCAS Google Scholar
Borrello I, Sotomayor EM, Cooke S, Levitsky HI. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines.Hum Gene Ther. 1999;10:1983–1991. ArticlePubMedCAS Google Scholar
Borrello IM, Sotomayor EM. Cancer vaccines for hematologic malignancies.Cancer Control. 2002;9:138–151. ArticlePubMed Google Scholar
Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.Blood. 2000;96:2917–2924. ArticlePubMedCAS Google Scholar
Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40- ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells.J Clin Invest. 1998;101:1133–1141. ArticlePubMedPubMed CentralCAS Google Scholar
Przepiorka D, Srivastava PK. Heat shock protein-peptide complexes as immunotherapy for human cancer.Mol Med Today. 1998; 4:478–484. ArticlePubMedCAS Google Scholar
Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future.Int J Cancer. 2001;94:459–473. ArticlePubMedCAS Google Scholar
Selenko N, Maidic O, Draxier S, et al. CD20 antibody (C2B8)- induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells.Leukemia. 2001;15:1619–1626. ArticlePubMedCAS Google Scholar
Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Anti-tumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.J Exp Med. 2002;195:125–133. ArticlePubMedPubMed CentralCAS Google Scholar
Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens.Immunity. 1999;10:281–287. ArticlePubMedCAS Google Scholar
Campbell MJ, Carroll W, Kon S, et al. Idiotype vaccination against murine B cell lymphoma: humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.J Immunol. 1987;139:2825–2833. PubMedCAS Google Scholar
George AJ, Tutt AL, Stevenson FK. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.J Immunol. 1987;138:628–634. PubMedCAS Google Scholar
Timmerman JM, Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.J Immunol. 2000;164:4797–4803. ArticlePubMedCAS Google Scholar
van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness.Blood. 2002;100:2257–2259. Article Google Scholar
Gonzalez-Stawinski GV, Yu PB, Love SD, Parker W, Davis RD Jr. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab).Clin Immunol. 2001;98:175–179. ArticlePubMedCAS Google Scholar
Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity.Nat Med. 1998;4:627–630. ArticlePubMedCAS Google Scholar
Timmerman JM. Vaccine therapies for non-Hodgkin’s lymphoma.Curr Treat Options Oncol. 2002;3:307–315. ArticlePubMed Google Scholar
Ruffini PA, Neelapu SS, Kwak LW, Biragyn A. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.Haematologica. 2002;87:989–1001. PubMed Google Scholar
Okada CY, Wong CP, Denney DW, Levy R. TCR vaccines for active immunotherapy of T cell malignancies.J Immunol. 1997;159: 5516–5527. PubMedCAS Google Scholar
Wong CP, Okada CY, Levy R. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.J Immunol. 1999;162:2251–2258. PubMedCAS Google Scholar
Hooijberg E, Visseren MJ, van den Berk PC, et al. Lysis of syn-geneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen-derived synthetic peptide.J Immunother Emphasis Tumor Immunol. 1996;19:346–356. ArticlePubMedCAS Google Scholar
Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice.Blood. 2002;99: 3748–3755. ArticlePubMedCAS Google Scholar
van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.Science. 1991;254:1643–1647. ArticlePubMed Google Scholar
Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction.Immunol Today. 1997;18: 493–497. ArticlePubMedCAS Google Scholar